Sustainably released nanoparticle-based rhynchophylline limits pulmonary fibrosis by inhibiting the TEK-PI3K/AKT signaling pathway

BACKGROUND: Pulmonary fibrosis (PF) is a rapidly progressing and irreversible disease, and the currently available types of clinical drugs are limited and inefficient. In our previous study, we observed that Rhynchophylline (Rhy) hindered tendon adhesion and stimulated the healing of injured tendon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuo, Huang, Zhanghao, Liu, Yifei, Sun, Hui, Zhou, Youlang, Shi, Jiahai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087999/
https://www.ncbi.nlm.nih.gov/pubmed/37057119
http://dx.doi.org/10.21037/tlcr-22-675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087999/
https://www.ncbi.nlm.nih.gov/pubmed/37057119
http://dx.doi.org/10.21037/tlcr-22-675

Ejemplares similares